Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

AusperBio Approved to Start US Trials of Antisense Oligonucleotide for Hepatitis B

publication date: Aug 25, 2023

AusperBio announced its lead drug, an antisense oligonucleotide (ASO) that targets all HBV RNA, was approved to start US trials in patients with chronic hepatitis B.  The company says AHB-137 is a potential best-in-class, highly potent, pan-genotypic ASO that has been well-tolerated in New Zealand and China trials. ASO compounds can bind messenger RNAs (mRNAs) with the goal of inhibiting mRNA translation in inflammatory and neoplastic diseases. The US trial is part of a multiregional, placebo-controlled study. AusperBio is headquartered in Hangzhou with additional operations in San Francisco. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital